Amylyx Pharmaceuticals, Inc. (AMLX) Tops Q4 EPS by 1c
Tweet
Share
E-mail
Get Alerts AMLX Hot Sheet
Join SI Premium – FREE
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) reported Q4 EPS of ($0.55), $0.01 better than the analyst estimate of ($0.56). Revenue for the quarter came in at $0 versus the consensus estimate of $0 .
For earnings history and earnings-related data on Amylyx Pharmaceuticals, Inc. (AMLX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
- ICICI Securities Starts Cemindia Projects (CEMPRO:IN) at Buy (1)
- Deutsche Bank Upgrades PennyMac Mortgage Investment Trust (PMT) to Buy
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
